| Prev Close | 2.70 |
| Open | 2.70 |
| Day Low/High | 2.70 / 2.86 |
| 52 Wk Low/High | 0.92 / 3.35 |
| Volume | 476.98K |
| Avg Volume | 799.90K |
| Exchange | NASDAQ |
| Shares Outstanding | 87.11M |
| Market Cap | 235.20M |
| EPS | -0.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
ArQule, Inc. (Nasdaq: ARQL) today announced that pre-clinical and clinical data on the company's pipeline of drug candidates will be presented at the 2018 AACR Annual Meeting taking place in Chicago from April 14-April 18.
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2017.
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will present at the 30 th Annual Roth Conference on March 12 th, 2018, at 5:00 p.
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018.
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.
Roivant Sciences and ArQule, Inc. (NASDAQ: ARQL) today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China.
ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma (iCCA).
ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017.
ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with institutional investors led by The Pontifax Group pursuant to which the Company raised gross proceeds of $9.
ArQule, Inc. (Nasdaq: ARQL) today announced that the U.
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017.
ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.
ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017.
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter 2017 before the market opens on Friday, August 4, 2017.
ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malignancies refractory to other approved therapies.
ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress in Madrid, Spain.
ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with Overgrowth Diseases driven by genetic alterations of...
ArQule, Inc. (Nasdaq: ARQL) today announced that data from a phase 1/2 trial with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, presented at ASCO demonstrate a meaningful clinical benefit to intrahepatic...
ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models will be presented on June 23, 2017 at EHA Congress in Madrid, Spain.
ArQule, Inc. (Nasdaq: ARQL) today announced that data from the phase 1/2 trial in intrahepatic cholangiocarcinoma (iCCA) with fibroblast growth factor receptor (FGFR) inhibitor, ARQ 087, will be presented on June 3, 2017 at...
ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2017.
ArQule, Inc. (Nasdaq: ARQL) today announced that the U.
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter 2017 before the market opens on Wednesday, May 3, 2017.
ArQule, Inc. (Nasdaq: ARQL) today announced that it has received clearance from the U.
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.
ArQule, Inc. (Nasdaq: ARQL) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of...
ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2016.
